A late-stage trial of Eli Lilly’s weight loss drug Zepbound showed promising results in treating sleep apnea symptoms in obese adults, the company announced Wednesday, the latest findings ...
INDIANAPOLIS, Indiana: This week, Eli Lilly said that after conducting two late-stage trials, its weight-loss drug Zepbound has been proven to reduce sleep apnea episodes, paving the way for its ...
Tirzepatide, the active ingredient in Mounjaro and Zepbound, reduced sleep apnea symptoms for people with obesity. The drug improved sleep apnea symptoms whether or not people used a PAP machine.
Zepbound, a popular weight loss drug from Eli Lilly, may help people with sleep apnea. Based on recent findings, Eli Lilly plans to submit the material to the U.S. Food and Drug Administration to ...